What is Fitbit?
Fitbit is Google's biometric wearable product line, distinct from the Pixel Watch generation. Current product line includes Fitbit Charge 6 + Fitbit Sense + Fitbit Versa, with ECG cleared 2020 and PPG-based AFib detection cleared 2022. Google acquired Fitbit in 2021; the Premium subscription model (~$9.99/month or $79.99/year) unlocks AI-insights across both Fitbit and Pixel Watch hardware. Per DEPLOY's biometric cluster framework, Fitbit anchors the budget-tier cleared archetype: cohort's strongest cardiologist-validation-at-price-point gradient with substantive FDA portfolio at sub-$200 hardware tier.
Charge 6 / Sense / Versa
Current product lines
2020 ECG / 2022 AFib
FDA clearance milestones
~$159+
Charge 6 entry pricing
$9.99/mo or $79.99/yr
Fitbit Premium subscription
Acquired 2021
Google ownership
Mid-2026
Snapshot date
Fitbit: budget-tier cleared archetype + Google product-line context
Fitbit is Google's biometric wearable product line; current generations include Fitbit Charge 6 + Fitbit Sense + Fitbit Versa. Google acquired Fitbit in 2021, and Fitbit operates as a product line under Google ownership alongside Pixel Watch. The two are complementary, not competing, within Google's unified biometric portfolio.
Per DEPLOY's biometric cluster framework, Fitbit anchors the budget-tier cleared archetype: the cohort's strongest cardiologist-validation-at-price-point gradient with substantive FDA portfolio at sub-$200 hardware tier. Where Apple Watch operates the substantial-cleared archetype at $249-$799+ pricing, Fitbit operates substantial-cleared posture at Charge 6 entry pricing (~$159).
FDA portfolio: ECG cleared 2020 + PPG AFib 2022
Fitbit carries substantive cleared scope at price points well below cohort competitors:
- ECG cleared 2020: Fitbit Sense was the first Fitbit product with FDA-cleared ECG functionality; precedent set early in the consumer-wearable ECG cohort (after Apple Watch 2018).
- PPG-based AFib detection cleared 2022: passive AFib detection via photoplethysmography (PPG) signal analysis; covers Charge + Sense + Versa lines that carry PPG sensors.
- Adjacent feature clearances: skin temperature variation tracking (Sense + Sense 2); stress detection via EDA; sleep tracking metrics in the wellness-grade tier.
The portfolio breadth at sub-$200 hardware tier is editorially substantive: Fitbit delivers ECG + AFib detection clearance at a price point where general-wellness positioning is the cohort norm. Per DEPLOY's framework, the budget-tier cleared posture is the verification anchor that distinguishes Fitbit from cohort entrants with general-wellness positioning only.
Product + business model
Current product line (2026): Fitbit Charge 6 + Fitbit Sense + Fitbit Versa. Cap-flag: Per Agent A biometric Wave 1 finding, Fitbit's product line continues in 2026; trade-press speculation that Fitbit was being discontinued post-Google-acquisition is not supported by current product release cadence + active marketing. Fitbit is operating as a continuing Google biometric product line.
Pricing: Fitbit Charge 6 ~$159; Fitbit Sense $249; Fitbit Versa varies by SKU. Purchase + optional Fitbit Premium subscription ($9.99/month or $79.99/year) unlocks advanced health tracking + AI-insights. The Fitbit Premium subscription is shared with Pixel Watch; the unified Google biometric portfolio benefits from cross-product subscription consolidation. Verified consumer pricing transparency for the Fitbit tracker line lives at Fitbit Tracker pricing on the consumer surface (line-level slug covering Charge + Sense + Versa multi-variant family).
Validation evidence + cohort positioning
Fitbit carries substantial peer-reviewed validation depth across sleep tracking, heart rate, stress detection, and AFib detection. The cohort's strongest validation-at-price-point gradient: substantial peer-reviewed evidence base at hardware tier below cohort canonical reference (Apple Watch). Per DEPLOY's verified-vs-claimed framework, Fitbit sits at the budget-tier cleared archetype with structural distinction from general-wellness-positioned entrants.
Cohort positioning + contrasts
Per the biometric cluster framework, Fitbit anchors:
- Budget-tier cleared archetype: ECG + PPG AFib clearance at sub-$200 entry hardware pricing.
- Validation-at-price-point gradient: strongest peer-reviewed evidence base at hardware tier below cohort canonical reference.
- Google product-line continuation: Fitbit Charge + Sense + Versa product lines continue under Google ownership; complementary to Pixel Watch in unified biometric portfolio.
- Premium subscription cohort-pattern: purchase + optional subscription archetype alongside Withings + Pixel Watch.
Contrast with cohort peers:
- Apple Watch: substantial-cleared at $249-$799+; broader feature portfolio + largest validation base.
- Pixel Watch: first-of-kind-cleared at $349-$399; Google sibling product line.
- Oura: study-first; general-wellness only; required-membership at $349 + $5.99/month.
- Whoop: subscription-only; lighter ECG-only clearance + BPI Warning Letter.
- Withings: hybrid analog watch archetype with ECG cleared 2021 EU / OTC 2025 US.
- Garmin: lighter-cleared archetype; ECG-only clearance; purchase-only no subscription.
- Samsung Galaxy Watch: Korean cohort entrant; sleep apnea De Novo Feb 2024; Korea + EU vs US clearance gradient.
- Dexcom Stelo: glucose-biometric cell anchor; medical-sensor-with-AI-insight bridge.
For the canonical biometric cohort context, see the biometric cluster. For adjacent AI wearables cohort context, see what is an AI wearable. For the canonical category umbrella, see what is physical AI. For methodology canonical references applicable to Fitbit: verified-vs-claimed at within-entity granularity (within-Fitbit feature-level verification + CPSC Ionic recall historical context) + the 9-tier source-quality rubric (CPSC + FDA + Google IR primary-government-record source classification).
| Entity | FDA scope | Entry pricing | Validation depth |
|---|---|---|---|
Fitbit (Charge 6 / Sense / Versa) | ECG 2020 + PPG AFib 2022 + skin temp + EDA | ~$159+ Charge 6 | Strongest at price point |
Apple Watch (Series 10/Ultra 2/SE) | ECG/AFib 2018 + sleep apnea 2024 + hypertension 2025 | $249+ SE / $399+ Series 10 / $799+ Ultra 2 | Largest in cohort |
Pixel Watch 3 | Loss-of-Pulse Detection De Novo Feb 2025 | $349 (41mm) / $399 (45mm) | Growing (newer scope) |
Withings ScanWatch | ECG cleared 2021 EU / OTC 2025 US | Mid-tier ScanWatch line | Peer-reviewed; cohort-mature |
Garmin (Venu / Fenix / Forerunner) | ECG 510(k) 2023 only | Wide range across lines | Cohort-mature; sports-specific |
Samsung Galaxy Watch | ECG 2021 + AFib 2023 + sleep apnea De Novo Feb 2024 | Galaxy Watch 7 / Watch Ultra | Cohort-mature |
Frequently asked questions
- What is Fitbit?
Fitbit is Google's biometric wearable product line, distinct from the Pixel Watch generation. Current product line includes Fitbit Charge 6 + Fitbit Sense + Fitbit Versa. ECG cleared 2020 (Fitbit Sense first) + PPG-based AFib detection cleared 2022. Google acquired Fitbit in 2021; the Premium subscription model (~$9.99/month or $79.99/year) unlocks AI-insights across both Fitbit and Pixel Watch hardware. Per DEPLOY's biometric cluster framework, Fitbit anchors the budget-tier cleared archetype: cohort's strongest cardiologist-validation-at-price-point gradient with substantive FDA portfolio at sub-$200 hardware tier.
- Is Fitbit dead after Google acquired it?
No. Per Agent A biometric Wave 1 foundational finding, Fitbit's product line continues in 2026. Trade-press speculation that Fitbit was being discontinued post-Google-acquisition is not supported by current product release cadence + active marketing. Fitbit Charge 6 + Fitbit Sense + Fitbit Versa generations are current and supported. Fitbit operates as a continuing Google biometric product line; the Fitbit + Pixel Watch portfolio is unified rather than competing. Per DEPLOY's cap-flag-as-trust-signal, cohort framing should treat Fitbit as a continuing product line.
- Is Fitbit FDA-cleared?
Yes, across multiple feature domains. ECG cleared 2020 (Fitbit Sense was the first Fitbit product with FDA-cleared ECG functionality; precedent set early in consumer-wearable ECG cohort after Apple Watch 2018). PPG-based AFib detection cleared 2022 (passive AFib detection via photoplethysmography signal analysis; covers Charge + Sense + Versa lines that carry PPG sensors). Adjacent clearances: skin temperature variation tracking (Sense + Sense 2); stress detection via EDA; sleep tracking metrics in the wellness-grade tier. The portfolio breadth at sub-$200 hardware tier distinguishes Fitbit from cohort entrants with general-wellness positioning only.
- Is Fitbit better than Apple Watch?
Different cohort tiers + different price points. Fitbit (Charge 6 / Sense / Versa): budget-tier cleared archetype at $159+ entry pricing; ECG cleared 2020 + PPG AFib 2022; strongest validation-at-price-point gradient. Apple Watch (Series 10 / Ultra 2 / SE): substantial-cleared archetype at $249-$799+ pricing; broader cleared feature portfolio (ECG/AFib 2018 + sleep apnea 2024 + hypertension 2025); largest peer-reviewed validation base in cohort; cohort canonical reference. Per DEPLOY's framework, the buyer-intent question matters: Fitbit at sub-$200 with substantive FDA scope vs Apple Watch at higher tier with broader portfolio + larger validation base.
- How much is Fitbit Premium?
Fitbit Premium subscription is ~$9.99/month or $79.99/year. Premium unlocks advanced health tracking + AI-insights across both Fitbit and Pixel Watch hardware; the Google biometric portfolio benefits from cross-product subscription consolidation. Baseline biometric features (heart rate + steps + basic sleep tracking + ECG + PPG AFib detection per cleared scope) are available without subscription. The purchase + optional subscription structure is the cohort's purchase + optional archetype alongside Withings + Pixel Watch.
- Does Pixel Watch replace Fitbit?
No. Fitbit and Pixel Watch are complementary, not competing, within Google's unified biometric portfolio. Pixel Watch is positioned at first-of-kind-cleared archetype with Loss-of-Pulse Detection De Novo Feb 2025; $349-$399 pricing. Fitbit is positioned at budget-tier cleared archetype with ECG 2020 + PPG AFib 2022 portfolio; sub-$200 entry pricing on Charge 6. The Fitbit Premium subscription works across both product lines. Google's unified biometric strategy treats both lines as targeting structurally distinct buyer segments while sharing infrastructure (subscription + Google account integration + AI-insights layer).
Fitbit verified at budget-tier cleared archetype in biometric cohort. Charge 6 + Sense + Versa current product line; Google acquired 2021. FDA portfolio: ECG cleared 2020 + PPG AFib detection 2022 + adjacent clearances (skin temp + EDA + sleep). $9.99/mo or $79.99/yr Premium subscription shared with Pixel Watch. Strongest validation-at-price-point gradient in cohort; sub-$200 Charge 6 entry pricing with substantive FDA scope. 2026 product line continues per Agent A Wave 1 finding; trade-press discontinuation speculation not supported. How DEPLOY verifies →
Continue reading
What is Pixel Watch?
Google sibling product line; first-of-kind-cleared archetype; Loss-of-Pulse Detection De Novo Feb 2025; unified biometric portfolio.
Read article →
What is Apple Watch?
Substantial-cleared archetype + cohort canonical reference; broadest FDA portfolio across cardiac + sleep + hypertension domains.
Read article →
What is Withings?
Hybrid analog watch archetype with substantial-cleared-for-size position; ECG 2021 EU / OTC 2025 US.
Read article →
The biometric cluster
Biometric-primary + AI-augmented cohort framework; FDA-clearance gradient + cohort positioning across all archetypes.
Read article →
Compare alternatives
Fitbit Tracker consumer pricingFitbit registry entityPixel Watch explainer (Google sibling)Biometric cluster